Grifols (GRFS) Competitors

In the previous week, Insmed had 24 more articles in the media than Grifols. MarketBeat recorded 25 mentions for Insmed and 1 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat Insmed's score of 1.25 indicating that Grifols is being referred to more favorably in the news media.

Insmed currently has a consensus target price of $212.50, indicating a potential upside of 117.17%. Grifols has a consensus target price of $10.00, indicating a potential upside of 30.89%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Grifols.

Grifols has a net margin of 5.54% compared to Insmed's net margin of -144.44%. Grifols' return on equity of 6.21% beat Insmed's return on equity.

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Grifols has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Grifols has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Moderna presently has a consensus target price of $36.60, indicating a potential downside of 26.67%. Grifols has a consensus target price of $10.00, indicating a potential upside of 30.89%. Given Grifols' higher probable upside, analysts clearly believe Grifols is more favorable than Moderna.

Grifols has a net margin of 5.54% compared to Moderna's net margin of -143.55%. Grifols' return on equity of 6.21% beat Moderna's return on equity.

Grifols has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Grifols has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Moderna had 18 more articles in the media than Grifols. MarketBeat recorded 19 mentions for Moderna and 1 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat Moderna's score of 0.57 indicating that Grifols is being referred to more favorably in the news media.

Grifols presently has a consensus target price of $10.00, suggesting a potential upside of 30.89%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 6.19%. Given Grifols' higher possible upside, equities analysts plainly believe Grifols is more favorable than Viatris.

Grifols has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Grifols pays an annual dividend of $0.14 per share and has a dividend yield of 1.8%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Grifols pays out 73.7% of its earnings in the form of a dividend. Viatris pays out -184.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

79.9% of Viatris shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Grifols has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Grifols has a net margin of 5.54% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Grifols' return on equity.

In the previous week, Grifols and Grifols both had 1 articles in the media. Grifols' average media sentiment score of 1.89 beat Viatris' score of 1.87 indicating that Grifols is being referred to more favorably in the media.

Genmab A/S has lower revenue, but higher earnings than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

7.1% of Genmab A/S shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Grifols currently has a consensus price target of $10.00, suggesting a potential upside of 30.89%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 51.23%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Grifols.

In the previous week, Genmab A/S had 3 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Genmab A/S and 1 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat Genmab A/S's score of 0.47 indicating that Grifols is being referred to more favorably in the media.

Genmab A/S has a net margin of 21.05% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 15.34% beat Grifols' return on equity.

Grifols has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.